| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
66,921,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
1,212,774 |
Avg
Vol: |
1,000,279 |
| 52
Week Range: |
$38.26 - $93.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue™, Lyra®, FreshCells™, D3®, FastPoint®, ReadyCells®, Super E-Mix™, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Polan Mary Lake Ph D |
Director |
– • – |
2022-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
867 |
19,029 |
|
- |
|
| Widder Kenneth J |
Director |
– • – |
2022-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,028 |
17,060 |
|
- |
|
| Buechler Kenneth F |
Director |
– • – |
2022-05-10 |
4 |
OE |
$15.73 |
$122,694 |
D/D |
7,800 |
68,664 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2022-03-30 |
4 |
D |
$112.80 |
$17,033 |
D/D |
(151) |
8,683 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
434 |
8,834 |
|
- |
|
| Polan Mary Lake Ph D |
Director |
– • – |
2022-03-18 |
4 |
S |
$113.59 |
$173,227 |
D/D |
(1,525) |
18,162 |
|
11% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2022-02-10 |
4 |
D |
$95.34 |
$57,299 |
D/D |
(601) |
16,556 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,260 |
16,661 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2022-02-04 |
4 |
D |
$98.87 |
$194,378 |
D/D |
(1,966) |
15,897 |
|
- |
|
| Kroll Werner |
SVP, R&D |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,268 |
17,863 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2022-02-03 |
4 |
D |
$99.68 |
$14,454 |
D/D |
(145) |
15,486 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
593 |
15,631 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2022-02-03 |
4 |
D |
$99.68 |
$22,528 |
D/D |
(226) |
8,235 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
652 |
8,461 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2022-02-03 |
4 |
D |
$99.68 |
$277,310 |
D/D |
(2,782) |
22,857 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,616 |
25,639 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2022-02-03 |
4 |
D |
$99.68 |
$87,021 |
D/D |
(873) |
29,164 |
|
- |
|
| Bujarski Robert Joseph |
Chief Operating Officer |
• – – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,660 |
30,037 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2022-02-03 |
4 |
D |
$99.68 |
$187,598 |
D/D |
(1,882) |
505,926 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2022-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,795 |
507,808 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2022-02-01 |
4 |
D |
$102.32 |
$11,869 |
D/D |
(116) |
15,038 |
|
- |
|
| Ranalli Tamara A. |
SVP, Molecular Bus. Unit |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
473 |
15,154 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2022-02-01 |
4 |
D |
$102.32 |
$56,583 |
D/D |
(553) |
504,013 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,115 |
504,566 |
|
- |
|
| Hodges Michelle A. |
SVP, General Counsel |
• – – |
2022-02-01 |
4 |
D |
$102.32 |
$19,850 |
D/D |
(194) |
434 |
|
- |
|
799 Records found
|
|
Page 2 of 32 |
|
|
2.54 (6.4%) 
